2022

A study in collaboration with St. Anna CCRI shows that stem cell transplantation does not provide any advantage over chemotherapy in a specific form of leukemia.

Ana Kutschat selected for training program by EHA and EMBL-EBI (Vienna, 21.12.2022) The European Hematology Association (EHA) and EMBL’s European Bioinformatics Institute (EMBL-EBI) selected Ana Kutschat, postdoc in Davide Seruggia´s research group at St. Anna Children´s Cancer Research Institute (St. Anna CCRI) as one of only 20 favored young scientists to participate in the 2023

St. Anna Children’s Cancer Research Institute and its collaboration partner CeMM receive funding for a project aimed at providing tailored treatments for a type of childhood leukemia not adequately addressed by current therapy.

Prof. Christina Peters, MD, from St. Anna Children’s Hospital and St. Anna CCRI presents new data showing a dire need for immunotherapy strategies tackling high-risk childhood leukemia at the Annual Meeting of the American Society of Hematology (ASH). Other updates from the same study (FORUM) confirm the superiority of total body irradiation prior to stem cell transplantation and the use of transplants from matched unrelated donors in children under the age of four with high-risk acute lymphoblastic leukemia (ALL).

How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer. The authors of this review are stakeholders from all relevant fields, including Caroline Hutter, MD, PhD, scientist at St. Anna Children’s Cancer Research Institute, clinician at St. Anna Children’s Hospital and expert in the rare pediatric cancer Langerhans cell histiocytosis (LCH). Her goal is to test the most effective and tolerable MAP kinase inhibitor in a clinical trial, thus enabling rapid market approval and availability for children.

On hot track! Davide Seruggia and Ana Kutschat focus on new epigenetic factors associated with risk of developing childhood leukemia.

St. Anna CCRI attends “Better Medicines for Children Conference 2022” (Vienna, 20.10.2022) We are happy to attend the “EFGCP Better Medicines for Children Conference 2022” with Ruth Ladenstein (Principal Investigator at St. Anna CCRI) presenting the EU funded “European Rare Disease Research Coordination and Support Action – ERICA” in the panel discussion “Rare diseases –

This year, all three prizes, as well as the “best abstract of the conference” go to St. Anna Children’s Cancer Research Institute (St. Anna CCRI) and St. Anna Children’s Hospital!

Socializing, getting further education and screening job offers: This year’s Life Science Career Fair of the ÖGMBT offered a wide range of opportunities for students and graduates.

A great success! Dr. Eva König, principal investigator at St. Anna CCRI, is honored with the Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR) for her scientific work on the interaction between immune and cancer cells. The prize is awarded to recognize the achievements of young scientists already conducting independent research in the field of experimental and clinical pharmacology and to encourage their further development.